Nuvation Bio Inc. (NUVB) FY2025 10-K Annual Report
Nuvation Bio Inc. (NUVB) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Mar 2, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Nuvation Bio Inc. FY2025 10-K Analysis
Business Overview
- • Core business: Global oncology focused on developing novel small molecule therapies for difficult-to-treat cancers, leveraging medicinal chemistry and clinical data
- • New emphasis: U.S. commercial launch of IBTROZI (taletrectinib) for ROS1+ NSCLC approved June 2025, plus new Eisai partnership for European and other territories in 2026
Management Discussion & Analysis
- • Revenue and profitability data not disclosed in MD&A section
- • No segment performance details provided
Risk Factors
- • Regulatory risk: FDA approval and post-approval obligations for IBTROZI (taletrectinib) granted June 11, 2025 for ROS1+ NSCLC treatment
- • Geopolitical risk: Commercial partnerships in Japan (NK) and China (Innovent) expose revenue to MHLW and NMPA regulatory environments
Nuvation Bio Inc. FY2025 Key Financial MetricsXBRL
Revenue
$63M
▲ +699.0% YoY
Net Income
-$205M
▲ +64.0% YoY
Operating Margin
-338.7%
▲ +718861bp YoY
Net Margin
-325.3%
▲ +688845bp YoY
ROE
-66.9%
▲ +5552bp YoY
Total Assets
$595M
▲ +10.0% YoY
EPS (Diluted)
$-0.60
▲ +71.6% YoY
Operating Cash Flow
-$173M
▼ -33.0% YoY
Source: XBRL data from Nuvation Bio Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Nuvation Bio Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.